MIMS Education

SGLT2 inhibitors in heart failure management: Dissecting the path from diabetes to heart failure

CardiologyInternal MedicineEndocrinologyFamily MedicineGeneral Practice

CME Unit: 1 point | An analog clock in color black

1 hour |

21 Oct 2022

Back to courses list

Overview

About this course

Across major cardiovascular outcome trials, sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently reduced the risk of heart failure (HF) in patients with diabetes and established cardiovascular disease. This e-learning module provides an overview of the latest real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes.

Learning outcomes

Upon completion of the educational activity, participants should be able to:

Understand the burden of HF and the associated guidelines for its prevention
Apply real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes
Utilize the latest robust clinical evidence on the use of SGLT2 inhibitors for treating patients with HF, irrespective of diabetes status.

Topics covered

Global prevalence of HF and classification
Guidance on use of biomarkers to screen for patients at risk of HF
Key finding and implications for clinical practice of the EMPA-REG OUTCOME, DAPA-HF, and EMPEROR-Reduced studies
Role of SGLT2 inhibitors as renal protectants based on the CREDENCE study

1 CME Point Available

This module is accredited for 1 CME Point for medical practitioners enrolled in The Medical Council of Hong Kong’s Continuing Medical Education Programme for Practising Doctors who are not taking CME for Specialists.
This module is accredited for 1 CME Point for fellows of the Hong Kong College of Physicians.
Please note that this module will not earn CME credit for fellows of colleges not listed here.
A certificate can be downloaded upon successful completion. Please use the information on the certificate to claim your CME points.